{"id":783106,"date":"2023-09-11T12:44:48","date_gmt":"2023-09-11T16:44:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-completes-enrollment-of-phase-2-trial-for-next-generation-covid-19-vaccine-booster\/"},"modified":"2023-09-11T12:44:48","modified_gmt":"2023-09-11T16:44:48","slug":"geovax-completes-enrollment-of-phase-2-trial-for-next-generation-covid-19-vaccine-booster","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-completes-enrollment-of-phase-2-trial-for-next-generation-covid-19-vaccine-booster\/","title":{"rendered":"GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster"},"content":{"rendered":"
\n

\n
\n Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants<\/em>
\n <\/strong>\n <\/p>\n

ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) — via NewMediaWire<\/u><\/a> — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has met the enrollment target for its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine (ClinicalTrials.gov Identifier: NCT04639466<\/u><\/a>).<\/p>\n

The study is designed to evaluate the safety profile and immunogenicity of two GEO-CM04S1 dose levels administered as a COVID-19 vaccine booster among healthy individuals previously vaccinated with one of the FDA approved SARS-CoV-2 mRNA vaccines. The immunological responses measured throughout the study will include both the level of neutralizing antibodies against SARS-CoV-2 variants of concern and specific T cell responses.<\/p>\n

GEO-CM04S1 is a next-generation COVID-19 vaccine based on GeoVax\u2019s MVA viral vector platform, which supports the presentation of multiple vaccine antigens to the immune system in a single dose. GEO-CM04S1 encodes for both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2 and is specifically designed to induce both antibody and T cell responses to those parts of the virus less likely to mutate over time. The more broadly functional engagement of the immune system is designed to protect against severe disease caused by continually emerging variants of COVID-19. Vaccines of this format should not require frequent and repeated modification or updating.<\/p>\n

\u201cWe would like to thank everyone who partnered with us to complete this important clinical trial enrollment milestone, especially the study volunteers and research staff at our clinical sites in the United States,\u201d said David Dodd, GeoVax Chairman and CEO. \u201cWe believe the unique properties of GEO-CM04S1 potentially offer a more robust, durable degree of protection than the current authorized COVID-19 vaccines, not only as a booster vaccine to the currently authorized mRNA vaccines, but as a primary vaccine for highly vulnerable immunocompromised patients.\u201d<\/p>\n

\n Additional Ongoing Trials of GEO-CM04S1<\/strong>\n <\/p>\n

In addition to the booster vaccine trial for which patient enrollment was just completed, GEO-CM04S1 is being evaluated in two other Phase 2 clinical trials:<\/p>\n